Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...
Rocket Pharmaceuticals’ RP-A501 Shows Promising Long-Term Efficacy and Safety in Danon Disease Treatment: Buy Rating Affirmed
In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), ...
precisionmedicineonline11d
Rocket Pharma Starts Rolling BLA Submission for Fanconi Anemia Gene Therapy
RP-L102, which the firm designed to treat a form of disease caused by FANCA mutations, is already under review with the European Medicines Agency.
CNN11mon
Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals ... Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based ...
Hackaday7y
Light Replaces Electrons For Giant Vector-Graphics Asteroids Game
For all its simplicity, the arcade classic Asteroids was engaging in the extreme, with the ping of the laser, the rumble of the rocket ... part of Asteroids was the vector display.
Joplin Globe12d
Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today ...
Le Lézard11d
Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and ...